Advertisement

Topics

Kiniksa Pharmaceuticals, Ltd. Company Profile

08:21 EDT 23rd June 2018 | BioPortfolio


News Articles [496 Associated News Articles listed on BioPortfolio]

Kiniksa Pharmaceuticals Announces Closing of Initial Public Offering

Kiniksa Pharmaceuticals (Nasdaq:KNSA) announced today the closing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share. As quoted in the pre...

Kiniksa Pharmaceuticals Announces Pricing of Initial Public Offering

Kiniksa Pharmaceuticals announced today the pricing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share, before underwriting discounts and ...

Kiniksa licenses mavrilimumab from MedImmune

MedImmune LLC granted Kiniksa Pharmaceuticals Ltd. exclusive global rights to develop and sell the granulocyte macrophage colony stimulating factor (GM-CSF) antagonist mavrilimumab. Kiniksa also gets ...

Kiniksa Pharmaceuticals goes public with $142mm IPO

Kiniksa Pharmaceuticals Inc. (developing in-licensed candidates for autoinflammatory and autoimmune diseases) netted $142mm through its initial public offering of 8.48mm common shares at $18. The comp...

Kiniksa Pharmaceuticals raises $37.5mm in first tranche of Series A; closes round at $80mm

Specialty pharmaco Kiniksa Pharmaceuticals Inc. raised $37.5mm through the first tranche of its Series A round. Baker Brothers led and was joined by company officers and directors, and entities affili...

Kiniksa licenses Biogen's IL-31 antagonist

Biogen Inc. granted Kiniksa Pharmaceuticals Ltd. exclusive global rights to an interleukin-31 antagonist, which Kiniksa named KPL716. The deal also includes patents and other intellectual property rig...

Regeneron grants rilonacept rights to Kiniksa

Regeneron Pharmaceuticals Inc. granted Kiniksa Pharmaceuticals Ltd. exclusive rights to develop and sell rilonacept, an interleukin-1b antagonist, worldwide excluding Israel, Turkey, and select Middle...

Biotech IPOs Roll On as Kiniksa, Scholar Rock Get $227M Combined

The IPO window remains wide open for biotechs. Two more, Kiniksa Pharmaceuticals and Scholar Rock, make their Wall Street debuts this morning having raised $227 million combined in their IPOs last nig...

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [133 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?

Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause ...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines and Pharmaceuticals.

Methods to incorporate deuterium and tritium atoms into organic molecules are valuable for medicinal chemistry. The prevalence of pyridines and diazines in pharmaceuticals means that new ways to label...

Environmental concentrations of pharmaceuticals directly affect phytoplankton and effects propagate through trophic interactions.

Pharmaceuticals are found in freshwater ecosystems where even low concentrations in the range of ng Lmay affect aquatic organisms. In the current study, we investigated the effects of chronic exposure...

Clinical Trials [216 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1321 Associated Companies listed on BioPortfolio]

Kiniksa Pharmaceuticals, Ltd.

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

Avanir Pharmaceuticals

AVANIR Pharmaceuticals, formerly LIDAK Pharmaceuticals, is a development stage company organized to discover, develop, and market novel therapeutic products to treat human diseases.

More Information about "Kiniksa Pharmaceuticals, Ltd." on BioPortfolio

We have published hundreds of Kiniksa Pharmaceuticals, Ltd. news stories on BioPortfolio along with dozens of Kiniksa Pharmaceuticals, Ltd. Clinical Trials and PubMed Articles about Kiniksa Pharmaceuticals, Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kiniksa Pharmaceuticals, Ltd. Companies in our database. You can also find out about relevant Kiniksa Pharmaceuticals, Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record